Overview

  • Product name

  • Description

    Rabbit polyclonal to PPAR gamma
  • Host species

    Rabbit
  • Specificity

    No significant homology with PPAR alpha or NUC1.
  • Tested applications

    Suitable for: IHC, WB, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human, Pig
  • Immunogen

    Synthetic peptide corresponding to Mouse PPAR gamma aa 284-298.
    Sequence:

    MMGEDKIKFKHITPL


    Database link: P37238

  • Positive control

    • 3T3-L1 differentiated cells and cell lysates

Applications

Our Abpromise guarantee covers the use of ab209350 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC Use at an assay dependent concentration.
WB 1/500 - 1/1000. Predicted molecular weight: 57 kDa.
ICC/IF 1/200.
EMSA Use at an assay dependent concentration.

Target

  • Function

    Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
  • Tissue specificity

    Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
  • Involvement in disease

    Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
    Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
    Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
    Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
  • Sequence similarities

    Belongs to the nuclear hormone receptor family. NR1 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • Cellular localization

    Nucleus.
  • Information by UniProt
  • Database links

  • Alternative names

    • CIMT1 antibody
    • GLM1 antibody
    • NR1C3 antibody
    • Nuclear receptor subfamily 1 group C member 3 antibody
    • OTTHUMP00000185032 antibody
    • OTTHUMP00000185036 antibody
    • Peroxisome proliferator activated nuclear receptor gamma variant 1 antibody
    • Peroxisome proliferator activated receptor gamma 1 antibody
    • Peroxisome Proliferator Activated Receptor gamma antibody
    • Peroxisome proliferator-activated receptor gamma antibody
    • PPAR gamma antibody
    • PPAR-gamma antibody
    • PPARG antibody
    • PPARG_HUMAN antibody
    • PPARG1 antibody
    • PPARG2 antibody
    • PPARgamma antibody
    see all

Images

  • Immunocytochemical analysis of PPAR gamma using ab209350 at the dilution 1/200. 3T3-L1 cells providing positive signal have been differentiated for 7 days.

    PPAR gamma is shown in red, lipid droplets (that indicates the proper differentiation of the cells) are shown in green.

  • All lanes : Anti-PPAR gamma antibody (ab209350)

    Lane 1 : NIH/3T3 cell lysate
    Lane 2 : HeLa cell lysate
    Lane 3 : K562 cell lysate
    Lane 4 : PC-12 cell lysate
    Lane 5 : U-87 MG cell lysate

    Predicted band size: 57 kDa

  • All lanes : Anti-PPAR gamma antibody (ab209350) at 1/500 dilution

    Lane 1 : 3T3
    Lane 2 : 3T3-L1 differentiated day 7

    Lysates/proteins at 20 µg per lane.

    Predicted band size: 57 kDa



    Specific band detected in 3T3-L1 day 7 differentiated lysate with no reactivity in 3T3 lysate.

  • Immunocytochemical analysis of PPAR gamma using ab209350 at the dilution 1/200.The image at the top shows 3T3-L1 cells differntiated (for 7 days) where PPAR gamma is shown in green. The image below shows 3T3-L1 undifferentiated cells where no PPAR gamma is detected.

References

This product has been referenced in:

  • Tao L  et al. Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. Mol Cell Endocrinol 481:95-103 (2019). Read more (PubMed: 30503377) »
  • Li Y  et al. Rosiglitazone attenuates cell apoptosis through antioxidative and anti-apoptotic pathways in the hippocampi of spontaneously hypertensive rats. Int J Mol Med 43:693-700 (2019). Read more (PubMed: 30483729) »
See all 22 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab209350.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up